You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百濟神州(06160.HK)獲Assembly Bio三款乙肝產品中國研發及商業化授權
阿思達克 07-21 09:45
百濟神州(06160.HK)宣布,與Assembly Biosciences達成合作協定,將獲得Assembly旗下三款產品於中國獨家研發及商業化的權利。公司則向Assembly支付4,000萬美元的現金預付款,及最多5億美元的潛在開發、藥政及銷售里程碑付款。百濟亦需支付未來淨銷售額的分級特許使用費。

該等產品為ABI-H0731、ABI-H2158及ABI-H3733,是用於治療慢性乙型肝炎感染的臨床階段核心抑制劑,其中ABI-H0731以及ABI-H2158目前正處於2期臨床試驗開發階段,而ABI-H3733正在進行1期臨床開發。百濟神州將為在中國的臨床開發注入初始資金,但此後在協定地區的開發成本將由雙方攤分。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account